- The shares in BioLife Solutions have crashed with the markets and some minor disappointments in quarterly figures.
- But we think the company has several secular tailwinds blowing in its favor and we see attractive valuation at these levels.
- There are signs that clinical trials are aborted because of the strain on the healthcare system, which is a negative.
- We do think the shares offer good value for investors with a longer-time horizon at these levels.
BioLife Will Suffer From Cancellations Of Trials
April 11th, 2020 · No Comments